99 related articles for article (PubMed ID: 7677336)
1. A new therapeutic approach for sickle cell disease. Blockade of the red cell Ca(2+)-activated K+ channel by clotrimazole.
Brugnara C; De Franceschi L; Armsby CC; Saadane N; Trudel M; Beuzard Y; Rittenhouse A; Rifai N; Platt O; Alper SL
Ann N Y Acad Sci; 1995 Jul; 763():262-71. PubMed ID: 7677336
[No Abstract] [Full Text] [Related]
2. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.
De Franceschi L; Saadane N; Trudel M; Alper SL; Brugnara C; Beuzard Y
J Clin Invest; 1994 Apr; 93(4):1670-6. PubMed ID: 7512989
[TBL] [Abstract][Full Text] [Related]
3. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.
Brugnara C; Gee B; Armsby CC; Kurth S; Sakamoto M; Rifai N; Alper SL; Platt OS
J Clin Invest; 1996 Mar; 97(5):1227-34. PubMed ID: 8636434
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease.
Brugnara C
Curr Opin Hematol; 1995 Mar; 2(2):132-8. PubMed ID: 9371983
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity.
Brugnara C; Armsby CC; Sakamoto M; Rifai N; Alper SL; Platt O
J Pharmacol Exp Ther; 1995 Apr; 273(1):266-72. PubMed ID: 7714775
[TBL] [Abstract][Full Text] [Related]
6. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
Stocker JW; De Franceschi L; McNaughton-Smith GA; Corrocher R; Beuzard Y; Brugnara C
Blood; 2003 Mar; 101(6):2412-8. PubMed ID: 12433690
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.
Brugnara C; de Franceschi L; Alper SL
J Clin Invest; 1993 Jul; 92(1):520-6. PubMed ID: 8326017
[TBL] [Abstract][Full Text] [Related]
8. Sickle cell disease: a step closer to the dream.
Mohandas N; Paszty C
J Clin Invest; 1996 Mar; 97(5):1135. PubMed ID: 8636422
[No Abstract] [Full Text] [Related]
9. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity.
Romero JR; Suzuka SM; Nagel RL; Fabry ME
Blood; 2002 Feb; 99(4):1103-8. PubMed ID: 11830454
[TBL] [Abstract][Full Text] [Related]
10. [Clinical trials of new therapeutic pharmacology for sickle cell disease].
Brugnara C; de Franceschi L
Sante; 2006; 16(4):263-8. PubMed ID: 17446160
[TBL] [Abstract][Full Text] [Related]
11. Prevention of red cell dehydration: a possible new treatment for sickle cell disease.
Mueller BU; Brugnara C
Pediatr Pathol Mol Med; 2001; 20(1):15-25. PubMed ID: 12673842
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
McNaughton-Smith GA; Burns JF; Stocker JW; Rigdon GC; Creech C; Arrington S; Shelton T; de Franceschi L
J Med Chem; 2008 Feb; 51(4):976-82. PubMed ID: 18232633
[TBL] [Abstract][Full Text] [Related]
13. Differences in the actions of some blockers of the calcium-activated potassium permeability in mammalian red cells.
Benton DC; Roxburgh CJ; Ganellin CR; Shiner MA; Jenkinson DH
Br J Pharmacol; 1999 Jan; 126(1):169-78. PubMed ID: 10051133
[TBL] [Abstract][Full Text] [Related]
14. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease.
Bennekou P; de Franceschi L; Pedersen O; Lian L; Asakura T; Evans G; Brugnara C; Christophersen P
Blood; 2001 Mar; 97(5):1451-7. PubMed ID: 11222393
[TBL] [Abstract][Full Text] [Related]
15. Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies.
De Franceschi L; Brugnara C; Rouyer-Fessard P; Jouault H; Beuzard Y
Blood; 1999 Dec; 94(12):4307-13. PubMed ID: 10590075
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of second messenger pathways and Ca(2+)-induced exposure of phosphatidylserine in red blood cells of patients with sickle cell disease.
Gbotosho OT; Cytlak UM; Hannemann A; Rees DC; Tewari S; Gibson JS
Pflugers Arch; 2014 Jul; 466(7):1477-85. PubMed ID: 24158429
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-chloro-2,4-dinitrobenzene on K+ transport in normal and sickle human red blood cells.
Muzyamba MC; Gibson JS
J Physiol; 2003 Mar; 547(Pt 3):903-11. PubMed ID: 12576491
[TBL] [Abstract][Full Text] [Related]
18. Additive in vitro effects of anti-sickling drugs.
Stuart J; Mojiminiyi FB; Stone PC; Culliford SJ; Ellory JC
Br J Haematol; 1994 Apr; 86(4):820-3. PubMed ID: 7918079
[TBL] [Abstract][Full Text] [Related]
19. Effects of inhibitors of small- and intermediate-conductance calcium-activated potassium channels, inwardly-rectifying potassium channels and Na(+)/K(+) ATPase on EDHF relaxations in the rat hepatic artery.
Andersson DA; Zygmunt PM; Movahed P; Andersson TL; Högestätt ED
Br J Pharmacol; 2000 Apr; 129(7):1490-6. PubMed ID: 10742306
[TBL] [Abstract][Full Text] [Related]
20. N-acetylcysteine and clotrimazole inhibit sickle erythrocyte dehydration induced by 1-chloro-2,4-dinitrobenzene.
Shartava A; Shah AK; Goodman SR
Am J Hematol; 1999 Sep; 62(1):19-24. PubMed ID: 10467272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
